---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000741"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:34:17.831306+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum Q1 2023 LIVMARLI sales $29.1M, up 167% YoY; closed $316M convertible note

## Summary
- Net product sales for LIVMARLI $29.1M in Q1 2023 vs $10.9M in Q1 2022, a 167% increase.
- Total revenue $31.6M; operating expenses $58.7M; cash $232.1M as of March 31, 2023.
- FDA approved label expansion for LIVMARLI to include infants 3 months+ in Alagille syndrome.
- sNDA for LIVMARLI in PFIC accepted with PDUFA date December 13, 2023.
- Closed $316.3M upsized convertible notes offering at 4.00% due 2029; repurchased 9.75% royalty obligation.

## SEC filing metadata
- accession: 0001157523-23-000741
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/0001157523-23-000741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/a53394174.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000741
- JSON: https://secwatch.observer/filing/0001157523-23-000741.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000741.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported first quarter 2023 results: revenue $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million.
  - Period: first quarter 2023
  - Revenue: $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million
  - Result: reported results
  source text: Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/0001157523-23-000741-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.